The positive results from the Phase 2 trial of BXCL701 plus Keytruda for metastatic castration-resistant prostate cancer indicate that the drug could be a potential new treatment option. This could lead to increased sales and revenue for Bioxcel Therapeutics, which would likely have a positive impact on the company's stock price.